Xanthine oxidase inhibits growth of Plasmodium falciparum in human erythrocytes in vitro

J Clin Invest. 1991 Dec;88(6):1848-55. doi: 10.1172/JCI115506.

Abstract

Malaria parasites, unable to synthesize purine de novo, use host-derived hypoxanthine preferentially as purine source. In a previous study (1990. J. Biol. Chem. 265:6562-6568), we noted that xanthine oxidase rapidly and completely depleted hypoxanthine in human erythrocytes, not by crossing the erythrocyte membrane, but rather by creating a concentration gradient which facilitated hypoxanthine efflux. We therefore investigated the ability of xanthine oxidase to inhibit growth of FCR-3, a chloroquine-resistant strain of Plasmodium falciparum in human erythrocytes in vitro. Parasites were cultured in human group O+ erythrocytes in medium supplemented, as required, with xanthine oxidase or chloroquine. Parasite viability was assessed by uptake of radiolabeled glycine and adenosine triphosphate-derived purine into protein and nucleic acid, respectively, by nucleic acid accumulation, by L-lactate production, and by microscopic appearance. On average, a 90% inhibition of growth was observed after 72 h of incubation in 20 mU/ml xanthine oxidase. Inhibition was notably greater than that exerted by 10(-7) M chloroquine (less than 10%) over a comparable period. The IC50 for xanthine oxidase was estimated at 0.2 mU/ml, compared to 1.5 x 10(-7) M for chloroquine. Inhibition was completely reversed by excess hypoxanthine, but was unaffected by oxygen radical scavengers, including superoxide dismutase and catalase. The data confirms that a supply of host-derived hypoxanthine is critical for nucleic acid synthesis in P. falciparum, and that depletion of erythrocyte hypoxanthine pools of chloroquine-resistant malaria infection in humans. of chloroquine-resistant malaria infection in humans.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cells, Cultured
  • Chloroquine / pharmacology
  • Dose-Response Relationship, Drug
  • Erythrocytes / parasitology*
  • Glycine / metabolism
  • Humans
  • Hypoxanthine
  • Hypoxanthines / metabolism
  • Hypoxanthines / pharmacology
  • Plasmodium falciparum / drug effects*
  • Plasmodium falciparum / growth & development
  • Purines / metabolism
  • Superoxide Dismutase / pharmacology
  • Xanthine Oxidase / pharmacology*
  • Xanthine Oxidase / therapeutic use

Substances

  • Hypoxanthines
  • Purines
  • Hypoxanthine
  • Chloroquine
  • Superoxide Dismutase
  • Xanthine Oxidase
  • Glycine